Author:
Clamp A R, ,Mäenpää J,Cruickshank D,Ledermann J,Wilkinson P M,Welch R,Chan S,Vasey P,Sorbe B,Hindley A,Jayson G C
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM (2003) Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21: 291–297
2. Bolis G, Scarfone G, Villa A, Parazzini F (2001) Phase II trial of topotecan, carboplatin and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer. Gynecol Oncol 81: 331–333
3. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542–547
4. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22: 2461–2468
5. Cacciari N, Zamagni C, Martoni A (2000) The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer: is it possible only with peripheral blood stem support? Eur J Gynaecol Oncol 21: 84–85
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献